免疫检查点抑制剂和通过医疗保险覆盖的生存差异在转移性癌症患者中
Jingxuan Zhao1,2,3, Ilana Graetz2,3, David Howard2,3
1Department of Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.
JAMA network open
|July 7, 2025
概括
引入免疫检查点抑制剂 (ICI) 扩大了与私人保险患者相比,未保险的癌症患者的生存差距. 这凸显了改善保险获取和治疗负担能力的政策的需要.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 卫生经济学 卫生经济学
背景情况:
- 免疫检查点抑制剂 (ICI) 改善了癌症的生存率.
- 高昂的ICI成本给没有保险的个人带来了负担能力的挑战.
- 了解保险状况的生存差异至关重要.
研究的目的:
- 评估ICI引入对晚期癌症患者生存差异的影响.
- 为了比较不同健康保险覆盖群体 (私人,医疗补助,无保险) 的生存率变化.
主要方法:
- 使用国家癌症数据库 (2002-2019) 进行的连续横截面研究.
- 包括18-64岁的患有第四期黑色素瘤,NSCLC或RCC的患者.
- 倾向性得分加权差异差异 (DID) 分析检查了ICI批准前和后的2年总生存期.
主要成果:
- 黑色素瘤 (6.1个百分点) 和NSCLC (1.3个百分点) 的无保险和私人保险患者的生存差异扩大.
- 在医疗补助和私人保险患者之间没有观察到显著的生存差异变化.
- 在ICI批准后,无保险和私人保险患者的整体存活率增加.
结论:
- ICI的引入加剧了基于保险状况的生存不平等.
- 需要制定政策来扩大医疗保险覆盖范围,降低治疗费用.
- 解决财政障碍对于公平的癌症护理至关重要.
相关概念视频
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


